desogestrel 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
steroids, progestogens 818 54024-22-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Org 2969
  • desogestrel
  • cerazette
A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED).
  • Molecular weight: 310.48
  • Formula: C22H30O
  • CLOGP: 5.50
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 1
  • TPSA: 20.23
  • ALOGS: -5.01
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.32 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.584 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.191 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.323 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 25.061 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 0.350 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 0.130 % Moderate 0.73
herg hERG pIC50 4.985 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 35.400 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 111.944 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 0.590 % Moderate 0.73
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIM2,PRKDC,TEK,TGFBR1,ZAP70 25
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.169 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 86.696 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 0.390 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.210 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.180 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 71.450 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.410 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 0.370 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 1.706 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Dec. 10, 1992 FDA ORGANON USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pregnancy on oral contraceptive 84.79 17.16 23 17386 1092 90609946
Folliculitis 68.81 17.16 133 17276 204220 90406818
Meningioma 63.69 17.16 27 17382 5044 90605994
Muscle injury 54.65 17.16 111 17298 176543 90434495
Gastrointestinal disorder 52.53 17.16 137 17272 256550 90354488
Lower respiratory tract infection 50.49 17.16 133 17276 250526 90360512
Night sweats 47.27 17.16 87 17322 128679 90482359
Irritable bowel syndrome 46.89 17.16 115 17294 207333 90403705
Lip dry 44.58 17.16 74 17335 100881 90510157
Product dose omission issue 44.33 17.16 3 17406 291684 90319354
Drug ineffective 42.70 17.16 131 17278 1384167 89226871
Product label confusion 40.02 17.16 34 17375 22816 90588222
Gait inability 38.33 17.16 86 17323 146370 90464668
Deep vein thrombosis postoperative 35.49 17.16 55 17354 70754 90540284
Autoimmune disorder 34.88 17.16 57 17352 76687 90534351
Injury 34.05 17.16 99 17310 197250 90413788
Death 34.04 17.16 23 17386 456528 90154510
Vaginal haemorrhage 32.72 17.16 35 17374 31236 90579802
Peripheral venous disease 32.43 17.16 58 17351 83863 90527175
Hyperprolactinaemia 31.49 17.16 17 17392 5416 90605622
Finger deformity 31.25 17.16 35 17374 32862 90578176
Arterial intramural haematoma 30.37 17.16 7 17402 169 90610869
Lip swelling 29.91 17.16 37 17372 38573 90572465
Hepatocellular injury 29.57 17.16 32 17377 28926 90582112
Impaired healing 29.09 17.16 105 17304 234094 90376944
Blister 28.08 17.16 110 17299 254888 90356150
Grip strength decreased 27.22 17.16 57 17352 92519 90518519
Obesity 26.53 17.16 61 17348 105446 90505592
Congenital anomaly 26.42 17.16 16 17393 6331 90604707
Polymenorrhagia 25.72 17.16 5 17404 51 90610987
Lung disorder 25.66 17.16 75 17334 149808 90461230
XIth nerve injury 25.05 17.16 5 17404 59 90610979
Tracheal pain 24.90 17.16 5 17404 61 90610977
Cell death 24.81 17.16 12 17397 3043 90607995
Ill-defined disorder 24.76 17.16 85 17324 184806 90426232
Exposure keratitis 24.75 17.16 5 17404 63 90610975
Bursitis 24.60 17.16 68 17341 131586 90479452
Sleep disorder due to general medical condition, insomnia type 24.57 17.16 67 17342 128627 90482411
Nail disorder 24.34 17.16 42 17367 59025 90552013
Coeliac disease 24.26 17.16 36 17373 44574 90566464
Meningioma surgery 24.20 17.16 5 17404 71 90610967
Pregnancy 24.12 17.16 43 17366 62004 90549034
Duodenal ulcer perforation 23.99 17.16 95 17314 221193 90389845
Urinary tract infection 23.30 17.16 15 17394 305617 90305421
C-reactive protein abnormal 23.01 17.16 65 17344 127364 90483674
Stomatitis 22.93 17.16 109 17300 274589 90336449
Essential tremor 22.79 17.16 9 17400 1403 90609635
Peripheral swelling 22.50 17.16 146 17263 412960 90198078
Labelled drug-food interaction medication error 22.34 17.16 6 17403 274 90610764
Menstrual disorder 21.83 17.16 14 17395 6124 90604914
B-cell type acute leukaemia 21.65 17.16 7 17402 612 90610426
Acute kidney injury 21.47 17.16 18 17391 320369 90290669
Reversible cerebral vasoconstriction syndrome 21.39 17.16 12 17397 4118 90606920
Anaemia 21.08 17.16 22 17387 352780 90258258
Intermenstrual bleeding 20.99 17.16 16 17393 9207 90601831
Injection site pain 20.91 17.16 4 17405 173695 90437343
Maculopathy 20.82 17.16 10 17399 2496 90608542
Sleep disorder 20.64 17.16 84 17325 197946 90413092
Joint range of motion decreased 20.52 17.16 65 17344 135578 90475460
Back injury 20.33 17.16 34 17375 46588 90564450
Pregnancy on contraceptive 20.02 17.16 8 17401 1287 90609751
White blood cell count decreased 19.79 17.16 4 17405 167105 90443933
Musculoskeletal pain 19.76 17.16 75 17334 171176 90439862
C-reactive protein 19.53 17.16 27 17382 31340 90579698
Wheezing 19.52 17.16 94 17315 237986 90373052
Swollen tongue 19.36 17.16 33 17376 45923 90565115
Liver injury 19.10 17.16 74 17335 170493 90440545
Liver function test increased 19.10 17.16 47 17362 84808 90526230
Upper motor neurone lesion 19.02 17.16 5 17404 210 90610828
Hepatitis 19.01 17.16 42 17367 70697 90540341
Frostbite 18.73 17.16 5 17404 223 90610815
Nasal mucosal erosion 18.68 17.16 4 17405 68 90610970
Dehydration 18.66 17.16 7 17402 194440 90416598
Pruritus 18.65 17.16 172 17237 541353 90069685
Confusional state 18.34 17.16 132 17277 386073 90224965
Pericarditis 18.22 17.16 101 17308 270050 90340988
Mitochondrial myopathy 18.01 17.16 5 17404 259 90610779
Adverse reaction 17.65 17.16 25 17384 29687 90581351
Hypotension 17.58 17.16 22 17387 325375 90285663
Personality change 17.32 17.16 13 17396 7308 90603730

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pregnancy on oral contraceptive 94.97 20.68 23 16317 905 110572054
Folliculitis 92.81 20.68 119 16221 167534 110405425
Muscle injury 79.58 20.68 101 16239 140706 110432253
Irritable bowel syndrome 68.92 20.68 102 16238 164113 110408846
Gastrointestinal disorder 64.97 20.68 123 16217 241829 110331130
Lip dry 63.31 20.68 76 16264 100007 110472952
Night sweats 63.22 20.68 88 16252 133895 110439064
Lower respiratory tract infection 60.88 20.68 120 16220 242986 110329973
Injury 58.99 20.68 99 16241 177166 110395793
Gait inability 56.19 20.68 84 16256 136292 110436667
Autoimmune disorder 53.83 20.68 57 16283 65426 110507533
Duodenal ulcer perforation 53.57 20.68 95 16245 177605 110395354
Deep vein thrombosis postoperative 53.04 20.68 54 16286 59237 110513722
Acute kidney injury 46.33 20.68 18 16322 635412 109937547
Death 45.92 20.68 23 16317 698846 109874113
Product label confusion 45.86 20.68 33 16307 22644 110550315
Peripheral venous disease 45.39 20.68 59 16281 84058 110488901
Meningioma 44.32 20.68 20 16320 5645 110567314
Pericarditis 44.17 20.68 99 16241 219015 110353944
Impaired healing 42.04 20.68 91 16249 196626 110376333
Sleep disorder due to general medical condition, insomnia type 41.99 20.68 64 16276 105579 110467380
Pemphigus 41.08 20.68 95 16245 214475 110358484
Vaginal haemorrhage 40.73 20.68 32 16308 25042 110547917
Anti-cyclic citrullinated peptide antibody positive 39.82 20.68 85 16255 181899 110391060
Grip strength decreased 39.82 20.68 54 16286 80120 110492839
Liver injury 39.76 20.68 76 16264 150337 110422622
Blister 39.57 20.68 97 16243 227279 110345680
Finger deformity 38.81 20.68 35 16305 33057 110539902
Pregnancy 37.69 20.68 42 16298 51025 110521934
C-reactive protein abnormal 37.36 20.68 68 16272 129627 110443332
Drug ineffective 37.24 20.68 109 16231 1520431 109052528
Joint range of motion decreased 36.53 20.68 65 16275 121767 110451192
Helicobacter infection 36.45 20.68 82 16258 181795 110391164
Obesity 35.96 20.68 62 16278 113289 110459670
Ill-defined disorder 35.17 20.68 74 16266 156779 110416180
Bursitis 34.77 20.68 66 16274 129852 110443107
Glossodynia 34.76 20.68 91 16249 221913 110351046
Maternal exposure during pregnancy 33.50 20.68 98 16242 254785 110318174
Hypotension 33.25 20.68 18 16322 523831 110049128
Peripheral swelling 32.60 20.68 132 16208 403902 110169057
Contusion 31.89 20.68 91 16249 233270 110339689
Nail disorder 31.82 20.68 41 16299 57894 110515065
Systemic lupus erythematosus 31.72 20.68 96 16244 254242 110318717
Hand deformity 31.62 20.68 87 16253 218419 110354540
Lung disorder 31.52 20.68 77 16263 179970 110392989
Coeliac disease 30.98 20.68 35 16305 43152 110529807
Musculoskeletal pain 30.69 20.68 77 16263 182946 110390013
Musculoskeletal stiffness 30.67 20.68 101 16239 279721 110293238
Wheezing 30.58 20.68 95 16245 255135 110317824
Rheumatoid factor positive 30.55 20.68 63 16277 131577 110441382
Anaemia 30.31 20.68 22 16318 547064 110025895
Psoriatic arthropathy 30.13 20.68 80 16260 196681 110376278
Rheumatic fever 30.03 20.68 60 16280 122519 110450440
Arterial intramural haematoma 29.53 20.68 7 16333 251 110572708
Abdominal pain upper 28.91 20.68 115 16225 348996 110223963
Stomatitis 28.24 20.68 96 16244 270146 110302813
Lip swelling 28.05 20.68 36 16304 50631 110522328
Hypersensitivity 27.96 20.68 126 16214 403872 110169087
Polymenorrhagia 27.12 20.68 5 16335 50 110572909
Swollen joint count increased 26.84 20.68 46 16294 83615 110489344
Hip arthroplasty 26.81 20.68 37 16303 55776 110517183
C-reactive protein 25.99 20.68 27 16313 30304 110542655
Facet joint syndrome 25.67 20.68 49 16291 96779 110476180
Labelled drug-food interaction medication error 25.62 20.68 6 16334 204 110572755
Prescribed overdose 25.32 20.68 46 16294 87535 110485424
Back injury 25.18 20.68 33 16307 47366 110525593
Wound 25.12 20.68 84 16256 234353 110338606
Liver function test increased 24.95 20.68 46 16294 88502 110484457
Lower limb fracture 24.93 20.68 42 16298 75306 110497653
Wound infection 24.57 20.68 48 16292 96417 110476542
Pruritus 24.32 20.68 158 16182 581402 109991557
Blood cholesterol increased 24.22 20.68 71 16269 184714 110388245
Pregnancy on contraceptive 24.02 20.68 8 16332 1000 110571959
Urticaria 23.99 20.68 102 16238 318755 110254204
Sleep disorder 23.84 20.68 74 16266 198570 110374389
Dehydration 23.76 20.68 6 16334 279505 110293454
Dry mouth 23.55 20.68 74 16266 199874 110373085
Cell death 23.23 20.68 13 16327 5778 110567181
Contraindicated product administered 23.18 20.68 85 16255 248182 110324777
Reversible cerebral vasoconstriction syndrome 22.75 20.68 12 16328 4749 110568210
Essential tremor 22.69 20.68 9 16331 1849 110571110
Discomfort 22.18 20.68 76 16264 214631 110358328
Road traffic accident 22.15 20.68 49 16291 107349 110465610
Paraesthesia 22.01 20.68 90 16250 276431 110296528
Hepatocellular injury 22.00 20.68 32 16308 50610 110522349
Swelling 21.72 20.68 106 16234 350935 110222024
Hyperprolactinaemia 21.70 20.68 13 16327 6562 110566397
Maculopathy 21.52 20.68 10 16330 3017 110569942
White blood cell count decreased 21.37 20.68 4 16336 229386 110343573
Weight increased 21.34 20.68 120 16220 419524 110153435
Adverse reaction 21.25 20.68 24 16316 29570 110543389
Sepsis 21.12 20.68 11 16329 327335 110245624
Intermenstrual bleeding 21.06 20.68 13 16327 6921 110566038
Urinary tract infection 21.00 20.68 11 16329 326271 110246688
Arthropathy 20.88 20.68 91 16249 287431 110285528
Synovitis 20.86 20.68 88 16252 274004 110298955

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AA09 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AC09 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens
ATC G03FB10 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, sequential preparations
FDA CS M0447349 Progesterone Congeners
CHEBI has role CHEBI:49323 contraceptive drug
CHEBI has role CHEBI:49326 synthetic oral contraceptive
CHEBI has role CHEBI:59826 progestin
FDA EPC N0000175602 Progestin
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D003280 Contraceptives, Oral, Synthetic
MeSH PA D006728 Hormones
MeSH PA D011372 Progestins
MeSH PA D012102 Reproductive Control Agents

Related Drugs by ATC class:

G03AA Progestogens and estrogens, fixed combinations 17 drugs
chlormadinonedienogestdrospirenoneestetrolestradiolethinylestradioletynodiolgestodenelevonorgestrellynestrenolmedroxyprogesteronemegestrol acetate show all 17 →
G03AB Progestogens and estrogens, sequential preparations 10 drugs
chlormadinonedienogestestradiolethinylestradiolgestodenelevonorgestrellynestrenolmegestrol acetatenorethisteronenorgestimate
G03AC Progestogens 9 drugs
drospirenoneetonogestrellevonorgestrellynestrenolmedroxyprogesteronemegestrol acetatenorethisteronenorgestrienonequingestanol acetate
G03FB Progestogens and estrogens, sequential preparations 10 drugs
chlormadinonedydrogesteronelevonorgestrellynestrenolmedrogestonemedroxyprogesteronemegestrol acetatenomegestrolnorethisteronetrimegestone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Contraception indication 13197004
Amenorrhea off-label use 14302001 DOID:13938
Female hypogonadism syndrome off-label use 16041008
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Menorrhagia off-label use 386692008
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Uterine leiomyoma contraindication 95315005 DOID:13223
Deep venous thrombosis contraindication 128053003
Endometriosis contraindication 129103003
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of cervix contraindication 363354003 DOID:4362
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.93 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Progesterone receptor Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL
Sex hormone-binding globulin Secreted Kd 6.60 CHEMBL

External reference:

IDSource
4020568 VUID
N0000148270 NUI
D02367 KEGG_DRUG
22656 RXNORM
4020568 VANDF
C0057558 UMLSCUI
CHEBI:4453 CHEBI
CHEMBL1533 ChEMBL_ID
DB00304 DRUGBANK_ID
D017135 MESH_DESCRIPTOR_UI
40973 PUBCHEM_CID
7065 IUPHAR_LIGAND_ID
4384 INN_ID
81K9V7M3A3 UNII
4549 MMSL
d03780 MMSL
003956 NDDF
116074007 SNOMEDCT_US
126108008 SNOMEDCT_US
81K9V7M3A3 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MERCILON HUMAN OTC DRUG LABEL 2 72689-0020 TABLET 0.15 mg ORAL unapproved drug other 7 sections